News & Events
Insight Genetics Presents Poster at the 16th World Conference on Lung Cancer and Attends the World CDx Boston Summit
Insight Genetics, Inc. presented a poster on September 7 at the International Association for the Study of Lung Cancer’s 16th Annual World Conference on Lung Cancer in Denver. The poster, “Detection of Aberrant ALK Expression from Circulating Tumor Cells for Accurate Monitoring of ALK Driven Non-Small Cell Lung Cancer,” describes the detection of an RNA-based oncogenic biomarker from blood. The biomarker detection from blood was enabled by combining Insight Genetics’s proprietary ALK qPCR technology with Biocept, Inc.’s proprietary circulating tumor cell (CTC) capture technology. Identification of ALK fusion RNA from NSCLC patient blood represents an effective strategy for accurately monitoring biomarker status in NSCLC patient populations.
Insight Genetics will attend the 6th Annual World CDx Boston Summit from September 8-10. The event showcases the latest advancements in companion diagnostics and tailored therapies that are improving and refining personalized healthcare, and Insight Genetics will be available to discuss its current NSCLC and triple-negative breast cancer programs, and service offerings including custom assay design and development and specialized pharmaceutical services.